Mauro G. Mastropasqua

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

Viviana Galimberti, Bernard F. Cole, Stefano Zurrida et al. · The Lancet Oncology · 2013 · 1.2K citations · Full text

Ibcsg 23–01, Surgical Pathology, Sentinel-node Micrometastases +5

An International Ki67 Reproducibility Study

Mei‐Yin C. Polley, Samuel Leung, Lisa M. McShane et al. · JNCI Journal of the National Cancer Institute · 2013 · 588 citations · Full text

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 533 citations

Surgical Oncology, Breast Oncology, Medicine +7

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Giuseppe Viale, Meredith M. Regan, Eugenio Maiorano et al. · Journal of Clinical Oncology · 2007 · 452 citations · Full text

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Giuseppe Viale, Anita Giobbie‐Hurder, Meredith M. Regan et al. · Journal of Clinical Oncology · 2008 · 340 citations · Full text